Breadcrumb

[A18-08] Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-02-01 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 306 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G15-14] Lumacaftor/ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed

[A18-39] Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2018-05-02 Extract of dossier assessment 306 kBPDFdownload file
2018-05-02 Dossier assessment (German version) 592 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V [PDF, 306 kB]

Federal Joint Committee (G-BA)

2018-08-02 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close